Routine clinical care data for population pharmacokinetic modeling: the case for Fanhdi/Alphanate in hemophilia A patients-Reference-Cited by-同舟云学术

Routine clinical care data for population pharmacokinetic modeling: the case for Fanhdi/Alphanate in hemophilia A patients

Published:2019-05-21 Issue:5 Volume:46 Page:427-438
ISSN:1567-567X
Container-title:Journal of Pharmacokinetics and Pharmacodynamics
language:en
Short-container-title:J Pharmacokinet Pharmacodyn

Author:

Chelle Pierre,Yeung Cindy H. T.,Bonanad Santiago,Morales Muñoz Juan Cristóbal,Ozelo Margareth C.,Megías Vericat Juan Eduardo,Iorio Alfonso,Spears Jeffrey,Mir Roser,Edginton Andrea

Funder

Grifols SA

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology

Link

http://link.springer.com/content/pdf/10.1007/s10928-019-09637-4.pdf

Reference37 articles.

1. Diez JM, Caballero S, Belda FJ, Otegui M, Gajardo R, Jorquera JI (2009) Elimination capacity of a TSE-model agent in the manufacturing process of Alphanate/Fanhdi, a human factor VIII/VWF complex concentrate. Haemophilia 15:1249–1257. https://doi.org/10.1111/j.1365-2516.2009.02067.x

2. Davie E (1995) Biochemical and molecular aspects of the coagulation cascade. Thromb Haemost 74:1–6. https://doi.org/10.1056/NEJM200106073442307

3. Stonebraker JS, Bolton-Maggs PH, Soucie JM, Walkers I, Brooker M (2010) A study of variations in the reported haemophilia A prevalence around the world. Haemophilia 16:20–32. https://doi.org/10.1111/j.1365-2516.2009.02127.x

4. Iorio A, Marchesini E, Marcucci M, Stobart K, Chan AK (2011) Clotting factor concentrates given to prevent bleeding and bleeding-related complications in people with hemophilia A or B. Cochrane Database Syst Rev. https://doi.org/10.1002/14651858.cd003429.pub4

5. Nilsson I, Berntorp E, Löfqvist T, Pettersson H (1992) Twenty-five years’ experience of prophylactic treatment in severe haemophilia A and B. J Intern Med 232:25–32

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Kinetic Modeling for BT200 to Predict the Level of Plasma-Derived Coagulation Factor VIII in Humans;The AAPS Journal;2024-07-12

2. Dosing for Personalized Prophylaxis in Hemophilia A Highly Varies on the Underlying Population Pharmacokinetic Models;Therapeutic Drug Monitoring;2022-10

3. Influence of blood group and von Willebrand factor on population pharmacokinetics and dose individualization of recombinant factor VIII in Taiwanese patients with haemophilia A;Haemophilia;2022-01-20

4. Clinical benefits of a Bayesian model for plasma-derived factor VIII/VWF after one year of pharmacokinetic-guided prophylaxis in severe/moderate hemophilia A patients;Thrombosis Research;2021-09

5. Pediatric Dose Selection for Therapeutic Proteins;The Journal of Clinical Pharmacology;2021-06